Klaas Hoekman

6.4k total citations
102 papers, 5.2k citations indexed

About

Klaas Hoekman is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Klaas Hoekman has authored 102 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 32 papers in Cancer Research and 29 papers in Molecular Biology. Recurrent topics in Klaas Hoekman's work include Angiogenesis and VEGF in Cancer (18 papers), Cancer, Hypoxia, and Metabolism (14 papers) and Colorectal Cancer Treatments and Studies (11 papers). Klaas Hoekman is often cited by papers focused on Angiogenesis and VEGF in Cancer (18 papers), Cancer, Hypoxia, and Metabolism (14 papers) and Colorectal Cancer Treatments and Studies (11 papers). Klaas Hoekman collaborates with scholars based in Netherlands, United Kingdom and United States. Klaas Hoekman's co-authors include Herbert M. Pinedo, Henk M.W. Verheul, Giuseppe Giaccone, Henk J. Broxterman, Hester van Cruijsen, Tjeerd J. Postma, J.J. Heimans, O. L. M. Bijvoet, Socrates E. Papapoulos and C.C.P. Verstappen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Klaas Hoekman

101 papers receiving 5.0k citations

Peers

Countries citing papers authored by Klaas Hoekman

Since Specialization

Citations

This map shows the geographic impact of Klaas Hoekman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaas Hoekman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaas Hoekman more than expected).

Fields of papers citing papers by Klaas Hoekman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaas Hoekman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaas Hoekman. The network helps show where Klaas Hoekman may publish in the future.

Co-authorship network of co-authors of Klaas Hoekman

This figure shows the co-authorship network connecting the top 25 collaborators of Klaas Hoekman. A scholar is included among the top collaborators of Klaas Hoekman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaas Hoekman. Klaas Hoekman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors 2010 ·Clinical Cancer Research ·José Baselga, Andrés Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, Paul Hamberg, (unknown), Paul Elvin, Alan Swaisland, Renee Iacona, Josep Tabernero	95
2	Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours 2010 ·European Journal of Cancer ·Hester van Cruijsen, Emile E. Voest, Cornelis J.A. Punt, Klaas Hoekman, Petronella O. Witteveen, Martijn R. Meijerink, Thomas A. Puchalski, Jane Robertson, O. Saunders, Juliane M. Jürgensmeier, Carla M.L. van Herpen, Giuseppe Giaccone	47
3	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival 2008 ·Clinical Cancer Research ·Hester van Cruijsen, Astrid A.M. van der Veldt, (unknown), Dinja Oosterhoff, Henk J. Broxterman, Rik J. Scheper, Giuseppe Giaccone, John B.A.G. Haanen, Alfons J.M. van den Eertwegh, Epie Boven, Klaas Hoekman, Tanja D. de Gruijl	111
4	Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly 2006 ·Cancer ·Anke Petra Jellema, Ben J. Slotman, Martín Müller, C. René Leemans, Ludi E. Smeele, Klaas Hoekman, Neil K. Aaronson, Johannes A. Langendijk	36
5	The hemostatic system in angiogenesis 2005 ·Birkhäuser Basel eBooks ·Victor W.M. van Hinsbergh, Pieter Koolwijk, Klaas Hoekman	1
6	Role of Platelet Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Fluoropyrimidine Sensitivity and Potential Role of Deoxyribose‐1‐Phosphate 2004 ·Nucleosides Nucleotides & Nucleic Acids ·Michiel de Bruin, (unknown), Kees Smid, Kasper van der Born, Masakazu Fukushima, Klaas Hoekman, Herbert M. Pinedo, Godefridus J. Peters	12
7	Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts 2004 ·Clinical Cancer Research ·Yvette van Hensbergen, Henk J. Broxterman, Sareena Rana, P. J. van Diest, Monique C.A. Duyndam, Klaas Hoekman, Herbert M. Pinedo, Epie Boven	44
8	Systemic and Peritoneal Angiogenic Response After Laparoscopic or Conventional Colon Resection in Cancer Patients: A Prospective, Randomized Trial 2004 ·Diseases of the Colon & Rectum ·(unknown), Klaas Hoekman, Colin Sietses, B. Mary E. von Blomberg, S. Meijer, H. Jaap Bonjer, Miguel A. Cuesta	110
9	Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity 2003 ·British Journal of Cancer ·Michiel de Bruin, (unknown), Kasper van der Born, Frank A.E. Kruyt, Masakazu Fukushima, Klaas Hoekman, Herbert M. Pinedo, Godefridus J. Peters	62
10	Phase I and pharmacokinetic study of Yondelis™ (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours 2003 ·European Journal of Cancer ·Chris Twelves, Klaas Hoekman, A. Bowman, Jan B. Vermorken, Alan Anthoney, John Smyth, Charlotte van Kesteren, Jos H. Beijnen, (unknown), J. Wanders, Javier Gómez, C. Guzmán, José Jimeno, A.-R. Hanauske	75
11	Clinical and Preclinical Modulation of Chemotherapy-Induced Toxicity in Patients with Cancer 1999 ·Drugs ·Klaas Hoekman, W. J. F. van der Vijgh, Jan B. Vermorken	41
12	Peripheral Neuropathy Due to Biweekly Paclitaxel, Epirubicin and Cisplatin in Patients with Advanced Ovarian Cancer 1999 ·Journal of Neuro-Oncology ·Tjeerd J. Postma, Klaas Hoekman, J.M.G.H. van Riel, J.J. Heimans, Jan B. Vermorken	23
13	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy 1997 ·International Journal of Cancer ·Sabine C. Linn, Herbert M. Pinedo, J van Ark-Otte, Paul van der Valk, Klaas Hoekman, Aafke H. Honkoop, Jan B. Vermorken, Giuseppe Giaccone	7
14	A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. 1997 ·PubMed ·N Feller, Klaas Hoekman, Catharina M. Kuiper, Sabine C. Linn, Henk M.W. Verheul, B.G. Wolthers, C. Popp‐Snijders, Herbert M. Pinedo	9
15	Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease 1997 ·Annals of Oncology ·(unknown), Klaas Hoekman, Curt W. Burger, R. Verheijen, Jan B. Vermorken	25
16	Expression of drug resistance proteins in breast cancer, in relation to chemotherapy 1997 ·International Journal of Cancer ·Sabine C. Linn, Herbert M. Pinedo, J van Ark-Otte, Paul van der Valk, Klaas Hoekman, Aafke H. Honkoop, Jan B. Vermorken, Giuseppe Giaccone	84
17	Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain 1997 ·British Journal of Cancer ·HJ Broxterman, G.J. Schuurhuis, J. Lankelma, (unknown), CA Eekman, A.M.E. Claessen, Klaas Hoekman, Martin Poot, Herbert M. Pinedo	31
18	Chemotherapy for gynecologic malignancies 1995 ·Current Opinion in Oncology ·Jan B. Vermorken, Klaas Hoekman	10
19	Arginine supplementation in the prevention and treatment of osteoporosis 1994 ·Medical Hypotheses ·J. Visser, Klaas Hoekman	35
20	Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells 1991 ·Bone and Mineral ·Klaas Hoekman, Clemens W.G.M. Löwik, (unknown), O. L. M. Bijvoet, Jan H. Verheijen, Socrates E. Papapoulos	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact